Elotuzumab is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received 1 to 3 prior therapies; it functions as a first-in-class immunostimulatory monoclonal antibody targeting SLAMF7 (also known as CS1, CD319, or CRACC), exerting anti-myeloma activity primarily through antibody-dependent cellular cytotoxicity (ADCC) and activation of natural killer (NK) cells.